e such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies.
Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward- looking statements as a result of new information, future events or otherwise.
Contacts for Alliqua, Inc.
Steven Berger Page: 1 2 3 4 5 6 7 Related biology technology :1
Chief Financial Officer
. HealthEconomics.Com Announces Newsletter Promoting Health Outcomes and Pharma Reimbursement Jobs2
. HealthEconomics.Com Presents Top News Stories in Pharma Reimbursement and Pricing from this Week's Newsletter3
. Topical BioMedics' Newsletter Dedicated to Natural Healing and Wellness--New Issue Available Online4
. First Warning Systems and Unicorp Biotech International Strategic Partner Letter of Intent Signed Breast Cancer Early Detection5
. Amarantus BioSciences Issues CEO Letter to Shareholders6
. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals7
. Ronald L. Chez Files Amended 13D and Letter to the Board8
. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B9
. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders10
. Genesis Biopharma Issues Letter To Shareholders11
. NeoStems CEO Letter to Shareholders